Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Aurinia Pharmaceuticals Inc. (AUPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/30/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Material Change Report - - Collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd",
"Material Change Report - - Collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd",
"Otsuka-Aurinia Collaboration License Agreement"
12/21/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan"
11/20/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635"
11/10/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Three months ended Nine months ended September 30, 2020$",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2020",
"FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE",
"FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE"
11/10/2020 6-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights"
11/09/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020"
11/02/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome"
10/29/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "included with this report on Form 6-K is hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-238785), as amended or supplemented",
"included with this report on Form 6-K is hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-238785), as amended or supplemented"
10/22/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020"
10/14/2020 6-K Quarterly results
10/02/2020 6-K Quarterly results
09/28/2020 6-K Quarterly results
09/04/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635"
08/11/2020 6-K Quarterly results
08/11/2020 6-K Quarterly results
07/23/2020 6-K Quarterly results
07/22/2020 6-K Quarterly results
07/21/2020 6-K Quarterly results
06/22/2020 6-K Quarterly results
06/09/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020"
06/05/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress"
06/03/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Announces Results of Annual General Meeting"
05/26/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis"
05/14/2020 6-K Quarterly results
05/14/2020 6-K Quarterly results
04/28/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"AURINIA PHARMACEUTICALS INC. Notice of Annual General and Special Meeting of Shareholders NOTICE is hereby given that the Annual General and Special Meeting of shareholders of Aurinia Pharmaceuticals Inc. will be held as a virtual-only meeting via live webcast online using the LUMI meeting platform at https://web.lumiagm.com/153516206 on Tuesday, June 2, 2020, at 9:00 AM, Pacific Time, for the following purposes: 1. to fix the number of directors at nine; 2. to elect the directors for the ensuing year; 3. to receive the audited consolidated financial statements of the Company for the financial year ended December 31, 2019, and the report of the auditors thereon; 4. to re-appoint PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors of the Company; 5. to consider a non...",
"AURINIA PHARMACEUTICALS INC.",
"AURINIA PHARMACEUTICALS INC. NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON and MANAGEMENT INFORMATION CIRCULAR Dated April 21, 2020"
04/27/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Appoints Joe Miller as Chief Financial Officer"
04/20/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "included with this report on Form 6-K is hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-222413), as amended or supplemented",
"included with this report on Form 6-K is hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-222413), as amended or supplemented"
03/19/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings"
03/17/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "included with this report on Form 6-K is hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-222413), as amended or supplemented",
"included with this report on Form 6-K is hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-222413), as amended or supplemented"
03/16/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "AURINIA PHARMACEUTICALS INC. 6-K",
"Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis - Company remains on track to complete submission by the end of the second quarter 2020 -"
03/12/2020 6-K Quarterly results
03/05/2020 6-K Quarterly results
02/25/2020 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy